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Abstract. The aim of the present study was to enhance the 
efficiency of leukemia immunotherapy by increasing the 
antigen-specific cytotoxic T lymphocyte-inducing ability 
of leukemia cells. The leukemic plasmacytoid dendritic cell 
line PMDC05 containing the HLA-A02/24 antigen, which 
was previously established in our laboratory (Laboratory 
of Hematology and Oncology, Graduate School of Health 
Sciences, Niigata University, Niigata, Japan), was used in the 
present study. It exhibited higher expression levels of CD80 
following transduction with lentiviruses encoding the CD80 
gene. This CD80-expressing PMDC05 was named PMDC11. 
In order to establish a more potent antigen-presenting cell 
for cellular immunotherapy of tumors or severe infections, 
PMDC11 cells were transduced with a constitutively active 
(ca) toll-like receptor 4 (TLR4) gene using the Tet-On system 
(caTLR4-PMDC11). CD8+ T cells from healthy donors with 
HLA-A02 were co-cultured with mutant WT1 peptide-pulsed 
PMDC11, lipopolysaccharide (LPS)-stimulated PMDC11 or 
caTLR4-PMDC11 cells. Interleukin (IL)-2 (50 IU/ml) and 
IL-7 (10 ng/ml) were added on day three of culture. Priming 
with mutant WT1 peptide-pulsed PMDC11, LPS-stimulated 
PMDC11 or caTLR4-PMDC11 cells was conducted once per 
week and two thirds of the IL-2/IL-7 containing medium 
was replenished every 3-4 days. Immediately prior to the 
priming with these various PMDC11 cells, the cultured cells 
were analyzed for the secretion of interferon (IFN)-γ in addi-
tion to the percentage and number of CD8+/WT1 tetramer+ 
T cells using flow cytometry. caTLR4‑PMDC11 cells were 
observed to possess greater antigen-presenting abilities 
compared with those of PMDC11 or LPS-stimulated PMDC11 
cells in a mixed leukocyte culture. CD8 T cells positive for 
the WT1 tetramer were generated following 3-4 weeks of 
culture and CD8+/WT1 tetramer+ T cells were markedly 
increased in caTLR4-PMDC11-primed CD8+ T cell culture 
compared with PMDC11 or LPS-stimulated PMDC11-primed 
CD8+ T cell culture. These CD8+ T cells co-cultured with 
caTLR4-PMDC11 cells were demonstrated to secrete IFN-γ 
and to be cytotoxic to WT1-expressing target cells. These 
data suggested that the antigen‑specific cytotoxic T lympho-
cyte (CTL)-inducing ability of PMDC11 was potentiated 
via transduction of the caTLR4 gene. The present study also 
suggested that caTLR4-PMDC11 cells may be applied as 
potent antigen‑presenting cells for generating antigen‑specific 
CTLs in adoptive cellular immunotherapy against tumors and 
severe viral infections.
Introduction
Dendritic cells (DCs) are potent antigen-presenting cells 
(APCs), which can prime naïve T cells to differentiate into 
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antigen‑specific cytotoxic T lymphocytes (CTLs), which are 
involved in the immune reaction (1). By utilizing this function 
of DCs, DC-based cellular immunotherapy has been developed 
for use in anti-tumor therapy and has been approved for use in 
prostate cancer by the Food and Drug Administration (Silver 
Spring, MD, USA) (2). In addition to therapy involving direct 
administration of DCs to patients, adoptive specific cellular 
immunotherapy has been developed. This involves the infusion 
of antigen‑specific CTLs generated by priming lymphocytes 
with antigen-presenting DCs in vitro into patients, which has 
been demonstrated to be a promising novel therapeutic treat-
ment strategy in cancer (3). Although previous studies have 
supported this treatment option, it is technically difficult 
and labor-intensive to expand what is currently known about 
antigen‑specific CTLs in vitro. Adoptive immunotherapy using 
antigen‑specific CTLs may be more practical for anti-cancer 
treatment if the potent APCs were available at any time.
In a previous study by our group, a leukemic plasmacy-
toid dendritic cell (pDC) line, PMDC05, was established 
from pDC leukemia cells (4). The PMDC05 cells were 
antigen-presenting, which was shown to be enhanced by 
stimulation with lipopolysaccharides (LPS) (4). Previously, 
PMDC05 cells were demonstrated to undergo a morphological, 
surface-phenotypical and functional transformation from pDC 
to a myeloid DC (mDC) lineage following the stimulation with 
interleukin (IL)-3 or LPS (5). Furthermore, PMDC05 cells 
have been indicated to possess a potent ability to generate 
tumor antigen‑specific CTLs from normal peripheral blood 
(PB) CD8+ T cells in vitro (6). Yamahira et al (7) identified 
that an antigen-presenting ability equivalent to that of maxi-
mally activated PMDC05 could be invoked in PMDC05 cells 
via lentiviral vector-mediated transduction of CD80 genes. 
CD80 gene-transduced PMDC05 cells were termed PMDC11 
in the present study, and their antigen-presenting ability was 
potentiated by stimulation with LPS. The present study aimed 
to establish efficient and potent APCs by transducing the 
constitutively active (ca) toll-like receptor 4 (TLR4) gene into 
PMDC11 using the Tet-On system with a lentiviral vector.
Materials and methods
Cell culture. PMDC05 cells (4) and PMDC11 cells (7) were 
established in our laboratory (Laboratory of Hematology 
and Oncology, Graduate School of Health Sciences, Niigata 
University, Niigata, Japan). The cells were cultured in Iscove's 
modified Dulbecco's medium (IMDM; Invitrogen Life 
Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum 
(FBS; Nichirei Biosciences, Inc., Tokyo, Japan). For establishing 
the PMDC05 cells, and using both of the cell lines, written 
informed consent was obtained from the patient's spouse. The 
present study was approved by the ethics committee of the 
Faculty of Medicine, Niigata University (March 25, 2011).
Lentivirus production and titer determination. Virus produc-
tion was conducted using transient co-transfection into 
293T cells (American Type Culture Collection, Manassas, 
VA, USA) according to the method described previously (8). 
The lentiviruses were concentrated by ultracentrifuga-
tion at 82,700 x g for 120 min at 4˚C, typically resulting in 
titers of >108 transduction units/ml. The lentiviral titer was 
determined via the assessment of the viral p24 antigen 
concentration using an ELISA (Cell Biolabs, Inc., San Diego, 
CA, USA), and is hereafter expressed as µg of p24 equivalent 
units/ml. A measure of 1 µg p24 equivalent per ml corresponds 
to ~1-5x107 transduction units/ml using 293T cells as a refer-
ence line. p24 concentrations of pLVX-Tet-ON Advanced and 
pLVX-Tight-TLR4-IRES-GFP-PGK-Puro lentiviruses 
(Clontech Laboratories, Inc., Mountain View, CA, USA) used 
in the present study were 19.1 and 11.3 µg/ml, respectively. 
The lentiviruses were prepared by Dr Noriyuki Kasahara 
(CURE Vector Core & JCCC Vector Shared Resource Facility, 
University of California, Los Angeles, CA, USA).
Lentiviral vector transduction. Transduction of pLVX-Tet-ON 
Advanced vector into the PMDC11 cells was performed as 
previously described (9). A total of 5x105 PMDC11 cells were 
suspended in a 15-ml tube containing 200 µl lentiviral vector 
(19.1 µg/ml p24 core protein by ELISA) and protamine sulfate 
(Sigma‑Aldrich, St. Louis, MO, USA) at a final concentration 
of 5 µg/ml. Cells were centrifuged at 800 xg for 30 min and 
suspended in 800 µl 10% FBS-containing IMDM, and were 
subsequently transferred to a 12-well plate. The 12-well plate 
containing the cells was centrifgued at 800 x g for 30 min 
(PlateSpinII; Kubota, Tokyo, Japan), in order to enhance the 
transduction efficiency, and the cells were then incubated at 
37˚C overnight in the presence of 5% CO2. Cells were then 
carefully collected in 15-ml tubes and diluted with fresh media 
and centrifuged at 200 x g for 5 min. The supernatant was 
removed and 2 ml fresh medium was added to the tube. Cells 
were then transferred into a 35-mm culture dish and cultured 
for 24 h. PMDC11 cells transduced with pLVX-Tet-ON 
Advanced vector were selected by adding 400 mg/ml G418 
(Sigma-Aldrich) to the culture dish on the next day, followed by 
further culturing for 7-12 days. G418-selected PMDC11 cells 
were transduced with pLVX-Tight-TLR4-IRES-GFP-PGK-
Puro lentiviral vector using an almost identical method, with 
the exception of using two selection reagents [1 µg/ml puro-
mycin (Sigma-Aldrich) and G418]. The concentrations of G418 
and puromycin used in the present study were confirmed to 
be appropriate for PMDC11 cells by a titration assay (10). The 
selected PMDC11 cells were termed caTLR4-PMDC11.
Evaluation of Tet‑On system. The operation of the lenti-
viral Tet-On system with pLVX-Tet-ON Advanced vector 
and pLVX-Tight-TLR4-IRES-GFP-PGK-Puro vector was 
evaluated by culturing caTLR4-PMDC11 cells in G418/puro-
mycin-containing medium with various concentrations of 
doxycycline for 6 h to 3 days and analyzing the expression 
of green fluorescent protein (GFP) on doxycycline‑exposed 
caTLR4‑PMDC11 cells using a FACSCalibur flow cytometer 
(BD Biosciences, San Jose, CA, USA).
Stimulation of PMDC11 and caTLR4‑PMDC11. PMDC11 
cells (1.0x106 cells/ml) were stimulated with 0.1 µg/ml LPS 
for 24 h (PMDC11 + LPS), whereas caTLR4-PMDC11 cells 
(1.0x106 cells/ml) were activated with 1 µg/ml doxycycline for 
24 h (caTLR4-PMDC11*Dox) prior to further analysis.
Phenotype analysis. PMDC11 cells and caTLR-PMDC11 cells 
were stained with the following phycoerythrin (PE)-conjugated 
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monoclonal antibodies: mouse CD1a (cat. no. 1590; 
Immunotech, Marseille, France), rat CD40 (cat. no. 732138; 
Immunotech), mouse CD80 (cat. no. 560925; BD 
Biosciences), mouse CD83 (cat. no. 305307; BioLegend, San 
Diego, CA, USA), mouse CD86 (cat. no. 305405; BioLegend) 
and mouse HLA-DR (cat. no. 307605; BioLegend). Stained 
cells were assessed using the FACSCalibur flow cytometer 
and data were analyzed using CellQuestPro software (BD 
Biosciences).
Allogeneic mixed leukocyte culture (MLC). MLC was 
performed as described previously (4). Briefly, PMDC11 
cells or caTLR4-PMDC11 cells were irradiated with 30 Gy of 
l37Cs generated gamma irradiation (PS-3000SB Cs-137; Pony 
Industry Co., Ltd., Osaka, Japan) immediately prior to MLC. 
A total of 1x105 allogeneic peripheral blood mononuclear 
cells (PB‑MNCs) were co‑cultured in a 96‑well flat‑bottom 
microtiter plate (BD Biosciences) with graded numbers 
(0, 1,250, 2,500 and 5,000) of irradiated PMDC11 cells or 
caTLR4-PMDC11 cells. The co-cultured cells were pulsed 
with 0.5 µCi (18.5 KBq)/well of [methyl-3H]-thymidine 
(Perkin-Elmer, Inc., Waltham, MA, USA) on day five of 
culture and harvested with a cell harvester (Labo Mash; 
Futaba Medical, Inc., Tokyo, Japan) following overnight 
culture. Cellular proliferation was measured by 3H-thymidine 
incorporation with a liquid scintillation counter (LSC-5100; 
Hitachi Aloka Medical Ltd., Tokyo, Japan). The experiments 
were conducted in triplicate.
Interferon (IFN)‑γ assay using cytometric bead array (CBA). 
IFN-γ in the MLC supernatant was quantified using the CBA 
Human IFN-γ Flex Set Assay (BD Biosciences) according to 
the manufacturer's instructions. Briefly, the provided standard 
IFN-γ (BD Biosciences) or culture supernatant was added 
to IFN-γ Capture Beads and the mixture was incubated for 
1 h. PE-conjugated anti-human IFN-γ antibody (IFN-γ PE 
Detection Reagent) was added to the mixture, which was then 
incubated for 2 h. The mixture was washed and centrifuged at 
300 x g for 10 min at room temperature. The centrifuged pellet 
was then resuspended in 300 ml wash buffer. The FACSCalibur 
flow cytometer was set up with BD FACSComp version 5.1 
software and BD Calibrite beads (BD Biosciences). IFN-γ 
concentrations were indicated by their fluorescent intensities 
(Fl‑2) and were quantified using the standard reference curve 
provided for IFN-γ.
CTL induction using PMDC11 or caTLR4‑PMDC11. 
CD8+ T cells were separated from PB-MNCs of a normal 
person with HLA-A*24:02 using the fluorescein isothio-
cyanate (FITC)-conjugated CD8 monoclonal antibody and 
anti-FITC microbeads (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) according to the manufacturer's 
instructions. PMDC11 cells and caTLR4-PMDC11 cells 
were incubated with 10 mg/ml mutant (m) 9mer WT1 
peptides with antigenicity in the HLA-A*24:02+ individual 
(CYTWNQMNL; NeoMPS, Inc., San Diego, CA, USA) 
for 24 h. caTLR4-PMDC11 cells were exposed to 1 mg/ml 
Figure 1. Expression of antigen presentation-associated molecules in PMDC11 and caTLR4-PMDC11 cells. PMDC11, LPS-stimulated PMD11, caTLR4-PMDC11 
and doxycycline‑exposed caTLR4‑PMD11 cells were analyzed for the expression of antigen presentation‑associated molecules by flow cytometry. Histograms 
representative of three experiments are presented. PMDC11 and caTLR4-PMDC11 cells were treated with LPS (0.1 µg/ml) or doxycycline (1 µg/ml) for 24 h, 
respectively. Filled purple histograms represent staining with specific antibodies and open green histograms represent isotype‑matched controls. Values in the 
graphs indicate mean fluorescence intensities. LPS, lipopolysaccharide; Dox, doxycycline; GFP, green fluorescent protein.
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doxycycline during this incubation period for operating Tet-On 
system. CD8+ T cells (5x105/well) were co-cultured with 
30 Gy-irradiated PMDC11 cells or caTLR4-PMDC11 cells 
at a cell ratio of 2:1 in a six-well plate containing 2.5 ml 5% 
autologous serum-containing RPMI 1640 medium (Invitrogen 
Life Technologies). IL-2 (Shionogi & Co., Ltd., Osaka, Japan) 
and IL-7 (R&D Systems, Inc., Minneapolis, MN, USA) were 
added to the co‑culture on day three at a final concentration of 
50 U/ml and 10 ng/ml, respectively. A proportion of two thirds 
of the medium containing IL-2 and IL-7 was replenished 
every 2-3 days throughout the culture period. The co-culture 
was stimulated repeatedly every week with the same mWT1 
peptide-pulsed PMDC11 cells or caTLR4-PMDC11 cells. 
mWT1 tetramer analysis of the co-cultured lymphocytes was 
performed every week immediately prior to the addition of 
PMDC cells (11).
Cytotoxicity assay of co‑cultured CD8+ T cells. A cyto-
toxicity assay was conducted using flow cytometry with 
co-cultured CD8+ T cells as effector cells and T2A24 cells 
[transporter associated with antigen processing-deficient, 
HLA-A24-expressing human T, B-hybridoma cells] as the 
target cells. The T2A24 cells were donated by Dr Yoshiki 
Akatsuka (Department of Hematology, Fujita Health 
University, Toyoake, Aichi, Japan). Lentivirally GFP 
gene-transduced T2A24 cells, which were pulsed with 
mWT1 peptides for 24 h, were cultured with effector cells 
in RPMI 1640 without phenol red for 4 h at 37˚C in a fully 
humidified 5% CO2 atmosphere. Co-cultured cells (consisting 
of effector cells and target cells) were stained with 7-amino-
actinomycin D (7AAD; Sigma-Aldrich) immediately prior to 
flow cytometric analysis. Cells were acquired for 120 sec in 
all the samples and viable target cells (GFP+/7AAD-) were 
gated in an FL-1 (GFP)/FL-3 (7AAD) dot plot. The percentage 
cytotoxicity of the assay was calculated with the following 
formula: % Cytotoxicity=[(absolute number of viable target 
cells in the tube containing target cells only - absolute 
number of viable target cells in the sample tube)/absolute 
number of viable target cells in the tube containing target 
cells only] x100.
Statistical analysis. The statistical significance of differences 
between values was evaluated via one- and two-way analysis of 
variance, with GraphPad Prism version 5 software (GraphPad 
Software, Inc., La Jolla, CA, USA). P<0.05 was considered to 
indicate a statistically significant difference.
Results
A n t igen  presen ta t ion ‑ a sso c ia ted  m olecu les  o f 
caTLR4‑PMDC11 cells. With regard to the establishment 
of the conditions for driving the Tet-On system, caTLR4 
was observed to be highly expressed on caTLR4-PMDC11 
following 24-h incubation with 1 µg/ml doxycycline, in 
Figure 2. Antigen-presenting ability of PMDC11 and caTLR-PMDC11 cells. Antigen-presenting abilities of these stimulator cells were assayed by allogeneic 
mixed leukocyte culture using 3H-thymidine incorporation. Graded numbers of PMDC11, LPS-stimulated PMD11, caTLR4-PMDC11 or doxycycline-exposed 
caTLR4-PMD11 cells were used as stimulator cells and normal peripheral blood mononuclear cells (1x105/well) were the responder cells. Statistical differences 
between PMDC11 cells and other stimulator cells were evaluated by two-way analysis of variance. The values are expressed as the mean ± standard error of 
the mean. The two experiments not presented had similar results. cpm, count per minute; LPS, lipopolysaccharide; Dox, doxycycline.
Figure 3. IFN-γ production of PB-MNCs stimulated with PMDC11 or 
caTLR-PMDC11 cells. The IFN-γ concentration of MLC supernatant was 
assayed using the cytometric bead array human IFN-γ Flex Set Assay. A total 
of 1x104cells/well of PMDC11, LPS-stimulated PMD11, caTLR4-PMDC11 
or doxycycline-exposed caTLR4-PMD11 cells were used as stimulator cells 
and 1x105cells/well of normal PB-MNCs were used as responder cells in 
MLC over 5 days. The bar graph shows the mean concentration of IFN-γ. 
Statistical differences between groups were evaluated using one-way anal-
ysis of variance. The values are expressed as the mean ± standard error of 
the mean. IFN, interferon; PB-MNCs, peripheral blood mononuclear cells; 
MLC, mixed leukocyte culture; LPS, lipopolysaccharide; Dox, doxycycline.
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the presence of which caTLR4-PMDC11 cells were viable. 
Therefore, caTLR4 expression was induced with 1 µg/ml of 
doxycycline for 24 h in the subsequent experiments.
The expression of antigen presentation-associated 
molecules, including CD80, CD83, CD86 and HLA-DR, 
on PMDC11 cells was demonstrated to be enhanced by the 
stimulation with LPS for 24 h. caTLR4-PMDC11 cells without 
doxycycline exposure exhibited a marginal increase in CD80 
and HLA-DR expression, which was suggested to be due to 
a spontaneous and partial expression of caTLR4 in addition 
to GFP when the Tet-On system was inactive. By driving the 
Tet-On system with doxycycline in caTLR4-PMDC11, which 
was confirmed by the expression of GFP, the expression 
of CD80, CD83 and HLA-DR was enhanced to the level of 
LPS-stimulated PMDC11 cells (Fig. 1).
Antigen‑presenting ability of caTLR‑PMDC11. The 
antigen-presenting ability of caTLR4-PMDC11 cells with 
or without doxycycline exposure was compared with that of 
PMDC11 cells with or without LPS stimulation by performing 
MLC with 3H-thymidine incorporation. The antigen-presenting 
ability of PMDC11 cells was  identified  to be enhanced by 
stimulation with LPS. By transduction with the caTLR4 
gene, the antigen-presenting ability of PMDC11 cells was 
observed to increase (caTLR4-PMDC11 without doxycycline 
exposure). In addition, following exposure to doxycycline, 
the antigen-presenting ability of caTLR4-PMDC11 was 
increased. caTLR4-PMDC11 cells possessed greater than 
or equal antigen-presenting ability compared with that of 
the LPS-stimulated PMDC11 cells (Fig. 2). This enhanced 
antigen-presenting ability of caTLR4-PMDC11 cells without 
doxycycline exposure compared with that of PMDC11 cells 
was hypothesized to be due to spontaneous and partial expres-
sion of caTLR4 in the state of Tet-On system inactivity.
IFN‑γ production of caTLR‑PMDC11. IFN-γ production 
of lymphocytes stimulated by caTLR4-PMDC11 cells with 
or without doxycycline exposure was compared with that 
produced by PMDC11 cells with or without LPS stimulation 
by using the CBA Human IFN-γ Flex Set assay (Fig. 3). IFN-γ 
production of PMDC11-stimulated lymphocytes was observed 
to be enhanced by the culture of PMDC11 cells with LPS. By 
transduction with the caTLR4 gene, the lymphocyte-stimu-
lating ability of PMDC11 cells leading to the production of 
IFN-γ was increased (caTLR4-PMDC11 without doxycy-
cline exposure). In addition, in the presence of doxycycline, 
Figure 4. mWT1‑specific cytotoxic T‑lymphocyte induction by caTLR4‑PMDC11 cells. Normal PB‑CD8+ T cells were cultured with mWT1 peptide-pulsed 
PMDC11, LPS‑stimulated PMDC11 or doxycycline‑exposed caTLR4‑PMDC11 cells for five weeks. The co‑cultured cells were double stained with the 
FITC-conjugated CD8 antibody and PE-conjugated mWT1 tetramer. (A) mWT1 tetramer analysis of CD8+ T cells cultured with PMDC11, LPS-stimulated 
PMDC11 or doxycycline-exposed caTLR4-PMDC11 cells. Values in the dot plots represent the percentages of mWT1 tetramer+/CD8+ T cells (marked in 
red) among the cells in the lymphocyte gate of forward scatter/side scatter dot plots. Dot plots are representative of three experiments with similar results. 
(B) Percentages of mWT1 tetramer+/CD8+ T cells in the lymphocyte gate of the forward scatter/side scatter dot plots. (C) Total number (x104) of CD8+ mWT1 
tetramer+ cells in a well, which was calculated by the formula [(percentage of mWT1 tetramer+/CD8+ T cells among lymphocytes) x (total number of lympho-
cytes in culture well)]. LPS, lipopolysaccharide; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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the lymphocyte-stimulating ability of caTLR4-PMDC11 
cells leading to the production of IFN-γ was demonstrated 
to increase. Doxycycline-treated caTLR4-PMDC11 cells 
possessed equivalent levels of potency in mediating the 
production of IFN-γ by lymphocytes compared with those 
of LPS-stimulated PMDC11 cells (Fig. 3). The enhanced 
lymphocyte-stimulating ability of caTLR4-PMDC11 without 
doxycycline exposure leading to the production of IFN-γ 
compared with that of PMDC11 cells was suggested to be due 
to spontaneous and partial expression of caTLR4 in the state 
of Tet-On system inactivity.
mWT1‑specific CTL induction by caTLR4‑PMDC11 cells. 
The mWT1‑specific CTL-inducing ability of normal PB-CD8+ 
T cells was compared between the PMDC11, LPS-stimulated 
PMDC11 and doxycycline-treated caTLR4-PMDC11 cells as 
the stimulator cells. Following three to five weeks of co‑culture 
of CD8+ T cells and PMDC11 cells, doxycycline-treated 
caTLR4-PMDC11 cells generated an increased percentage 
and number of mWT1‑specific CTLs compared with that of 
PMDC11 or LPS-stimulated PMDC11 cells (Fig. 4).
Cytotoxicit y of mW T1‑specif ic CTLs induced by 
caTLR4‑PMDC11. Antigen-specific cytotoxicity of CTLs 
generated from normal CD8+ T cells by priming with mWT1 
peptide-pulsed PMDC11 cells, LPS-stimulated PMDC11 cells 
or doxycycline-exposed caTLR4-PMDC11 cells was evaluated 
by flow cytometric analysis using mWT1 peptide‑pulsed and 
GFP-transduced T2A24 cells as target cells. CD8+ T cells 
co-cultured with mWT1 peptide-pulsed caTLR4-PMDC11 
Figure 5. Cytotoxicity of mWT1‑specific CTLs induced by caTLR4‑PMDC11. mWT1‑specific cytotoxicity of CTLs generated from normal CD8+ T cells by 
priming with mWT1 peptide-pulsed PMDC11, LPS-stimulated PMDC11 or doxycycline-exposed caTLR4-PMDC11 cells was evaluated using GFP-transduced 
T2A24 cells pulsed with or without mWT1 peptide as target cells by flow cytometric analysis. Target cells were cultured with effector cells in RPMI 1640 
without phenol red for 4 h at 37˚C. Co‑cultured cells were stained with 7AAD and subjected to flow cytometric analysis. Cells were acquired for 120 sec 
and viable target cells (GFP+/7AAD-) were counted. The cytotoxicity was calculated using the following formula: [(absolute number of viable target cells in 
the tube containing target cells only - absolute number of viable target cells in the sample tube)/absolute number of viable target cells in the tube containing 
target cells only] x100%. (A) Flow cytometry-based cytotoxicity assay of CD8+ T cells cultured with three types of PMDC11 cells. Gated cells in the dot plots 
represent the number of viable target cells; two repetitions of the experiment produced similar results. (B) Cytotoxicity of CD8+ T cells cultured with three 
types of PMDC11 cells against mWT1 peptide-pulsed T2A24 cells. (C) Cytotoxicity of CD8+ T cells cultured with caTLR4-PMDC11 cells against T2A24 cells 
pulsed with or without mWT1 peptide. Statistical differences between the two experimental groups were evaluated by two-way analysis of variance. The values 
are expressed as the mean ± standard error of the mean. APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; LPS, lipopolysaccharide; GFP, green 
fluorescent protein; 7AAD, 7‑aminoactinomycin D.
  A
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cells for four weeks demonstrated an increased cytotoxicity 
against mWT1 peptide-pulsed target cells compared with 
that of CD8+ T cells co-cultured with mWT1 peptide-pulsed 
PMDC11 or LPS-stimulated PMDC11 cells (Fig. 5A and B). 
The differences among the PMDC11, LPS-stimulated 
PMDC11 and doxycycline-exposed caTLR4-PMDC11 
cells were suggested to be due to the increased percentage 
of mWT1-specific CTLs present in the co-cultured cells. 
Although non-specific cytotoxicity against T2A24 cells 
without mWT1 peptide loading was observed in CD8+ T cells 
co-cultured with mWT1 peptide-pulsed caTLR4-PMDC11 
cells, the percentage cytotoxicity against T2A24 cells loaded 
with the mWT1 peptide was significantly greater than that of 
non-loaded target cells at E:T ratios of 5:1 and 10:1 (P<0.01; 
Fig. 5C).
Discussion
Freely available APCs with standardized quality are required 
for the establishment of an efficient adoptive cellular immuno-
therapy method for use in tumors and severe viral infections. 
Although autologous monocyte-derived DCs (moDCs) are 
commonly used as APCs for use in immunotherapy, the 
preparation of a sufficiently large quantity is complex and the 
quality of moDCs varies between individuals (12). Artificial 
APCs using either acellular (13-16) or cell-based systems 
[e.g., Drosophila (17), mouse fibroblast (18,19), human erythro-
myeloid (20,21) or breast carcinoma (22) cell lines] have been 
introduced in place of moDCs. In these cell‑based artificial 
APCs, antigen presentation-associated molecules, including 
major histocompatibility class I (17-21), CD80 (17-19,21,22), 
intercellular adhesion molecule 1 (CD54) (17-19,21), lympho-
cyte function-associated antigen 3 (CD58) (18,19,21) or 
CD83 (21) require expression via cDNA transfection in order 
to reach sufficient levels of antigen‑presenting ability on these 
artificial APCs.
Additionally, a DC line with antigen-presenting ability 
may be used for the induction of anti-tumor or anti-viral CTLs. 
In order to do this, three cell lines are available, one of which 
is the PMDC05 cell line, which is derived from pDC leukemia 
cells. Another is a pDC line, GEN2.2, which has been reported 
to require a monolayer of irradiated (60 Gy) MS-5 feeder cells 
for growth (23); however, an additional study has suggested 
that it may be able to grow without feeder cells (24). The third 
cell line is CAL-1, which was originally established from a 
patient with blastic natural killer cell lymphoma. CAL-1 
cells are very similar to PMDC05 cells in morphology and 
surface phenotypes, in addition to producing a small quantity 
of IFN-α (25). Recently, CAL-1 was used for evaluating the 
efficacy of anti‑nuclear factor (NF)‑κB-treatment on blastic 
plasmacytoid dendritic cell neoplasms, which was associated 
with aberrant activation of the NF-κB pathway (26). With 
regard to GEN2.2, Aspord et al (27) demonstrated that the 
GEN2.2 cell line was able to stimulate increased levels of 
tumor/viral antigen‑specific and functional cytotoxic T cell 
responses in vitro. They additionally noted that this cell line 
resulted in an inhibition of tumor growth in a humanized mouse 
in vivo model. Furthermore, Aspord et al (27) indicated that 
the GEN2.2 vaccine had a greater efficacy than conventional 
myeloid DC-based vaccines and suggested that an allogeneic 
pDC line-based vaccine may be a novel therapeutic tool for 
clinical application in cancer treatment (27). GEN2.2 cells 
have additionally been observed to secrete Type I and III IFN 
in response to the hepatitis C virus pathogen-associated 
molecular patterns (28).
PMDC05 cells, which were established in our laboratory 
(Laboratory of Hematology and Oncology, Graduate School of 
Health Sciences, Niigata University), are APCs and are able to 
produce a small quantities of IFN-α when stimulated with CpG 
and influenza virus (29). By stimulation with LPS, PMDC05 
cells produce IL-12p70 and the antigen-presenting ability is 
markedly increased (5). PMDC05 cells are able to induce 
antigen-specific CTLs efficiently from normal PB-CD8+ 
T cells in the co-culture experiments using tumor antigen 
(mWT1 peptide) or viral antigen (CMVpp65 peptide) (6). 
Although PMDC05 cells have an antigen-presenting ability 
without stimulation, minimal expression of CD80 was 
detected on PMDC05 cells (4). Therefore PMDC05 cells were 
transduced with the CD80 gene using a lentiviral vector and 
the CD80-transduced PMDC05 cells were termed PMDC11 
cells, which were demonstrated to have a more potent 
antigen-presenting ability than that of PMDC05 cells (7).
Preliminary investigations demonstrated that the expres-
sion of antigen presentation-associated molecules and 
antigen-presenting ability were enhanced in PMDC11 cells 
via the activation of TLR4 by LPS. To further potentiate the 
antigen-presenting ability and antigen‑specific CTL‑inducing 
ability, the caTLR4 gene was transduced into PMDC11 cells in 
order to constitutively activate TLR4 signaling while avoiding 
the use of LPS. LPS is not preferable in a clinical setting due 
to its gram-negative bacterial endotoxin-origin.
With regard to caTLR4, Cisco et al (30) reported that 
transfection of caTLR4 RNA into DCs induced DC matura-
tion comparable to that driven by the potent cytokine mixture 
of TNF-α, IL-6, IL-1β and prostaglandin E2. caTLR4 
RNA-transfected DCs secreted IL-12 and TNF-α and matu-
ration marker expression was enhanced in them, resulting 
in an increase in allostimulatory and antigen‑specific T‑cell 
responses (30). Abdel-Wahab et al (31) demonstrated that 
co-transfection into DC with RNA of caTLR4 and tumor 
antigens induced tumor antigen-specific T-cell responses 
more efficiently than transfection of tumor antigen RNA in 
combination with maturation cytokines. Bonehill et al (32) 
reported an increase in T-cell stimulatory capacity of moDCs 
by co-electroporation with differing combinations of CD40L, 
CD70 and caTLR4-encoding mRNA.
In order to further potentiate the antigen-presenting 
and CTL-inducing ability of CD80-expressing PMDC11, 
a lentiviral vector expressing caTLR4 was transduced into 
PMDC11 cells. PMDC11 cells, which were transduced with 
the caTLR4-expressing vector, proliferated transiently for 
three weeks and then proceeded to apoptosis. Thus, PMDC11 
cells were subsequently transduced with a caTLR4 gene 
regulated by the Tet-On system (caTLR4-PMDC11). Normal 
CD8+ T cells were co-cultured with mWT1 peptide-pulsed 
PMDC11 or caTLR4-PMDC11 and primed with mWT1 
peptide-pulsed PMDC11 or caTLR4-PMDC11 every week. 
mWT1 tetramer+/CD8+ T cells were generated subsequent to 
2‑3 weeks of culture and were observed to be significantly 
increased in caTLR4-PMDC11-primed CD8+ T-cell culture, 
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compared with PMDC11-primed CD8+ T-cell culture. Identical 
results were obtained in experiments using CMVpp65 peptide 
instead of mWT1 peptide (data not shown). 
In conclusion, the results of the present study indicated 
that the antigen‑specific CTL-inducing ability of PMDC11 
was enhanced by caTLR4 gene transduction and that 
caTLR4-PMDC11 cells may be applied as potent APCs in 
order to generate antigen‑specific CTLs for adoptive cellular 
immunotherapy against tumors and severe viral infections.
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